SAN ANTONIO (EGMN) - The addition of the PARP inhibitor BSI-201 to chemotherapy with gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer resulted in a dramatic 50% reduction in the risk of death, compared with chemotherapy alone, in an updated analysis of a high-profile phase II study. These impressive phase II results with the poly (ADP [adenosine diphosphate]-ribose) polymerase (PARP) inhibitor have led to an ongoing, definitive, phase III registration study involving...